23:02 , Jul 25, 2019 |  BC Extra  |  Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

Janssen’s ponesimod tops Aubagio in Phase III  The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...
00:01 , Jun 26, 2019 |  BC Extra  |  Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data  Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
22:52 , May 2, 2019 |  BC Extra  |  Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

Biogen's ALS candidate reduces SOD1 protein levels in CSF  Biogen Inc. (NASDAQ:BIIB) will present on May 7 at the American Academy of Neurology meeting the interim Phase I/II data of tofersen that had prompted it...
19:25 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting NOX2 or FOXC1 to treat AML and CML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML) Cell culture and mouse studies suggest inhibiting NOX2 or its downstream mediator FOXC1 could help treat AML and CML. In AML cells from...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
17:30 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
23:05 , Nov 5, 2018 |  BC Extra  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
19:10 , Aug 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Patient sample and mouse studies suggest inhibiting NOX4 could help treat cancer. In samples from patients with squamous cell carcinoma of the head and neck (SCCHN), esophageal cancer, colorectal cancer, breast cancer or...
00:18 , Aug 8, 2017 |  BC Extra  |  Preclinical News

Researchers suggest inhibiting NOX4 could treat cancer

In a paper published in the Journal of the National Cancer Institute , researchers at the University of Southampton showed that inhibiting NADPH oxidase 4 (NOX4) in cancer-associated fibroblasts can abrogate the tumor-promoting function of...
18:23 , Jul 3, 2017 |  BC Week In Review  |  Clinical News

Genkyotex begins Phase II of GKT831 in PBC

Genkyotex S.A. (Euronext:GKTX) began a Phase II trial to evaluate once- and twice-daily 400 mg GKT831 (formerly GKT137831) for 24 weeks in 102 patients with primary biliary cholangitis (PBC) and an inadequate response to ursodeoxycholic...